NCT03071081View on ClinicalTrials.gov

Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 8, 2017

Primary Completion Date

June 2, 2017

Study Completion Date

June 2, 2017

Conditions
Ulcerative Colitis
Interventions
DRUG

TOP1288

Oral TOP1288

DRUG

Placebo to TOP1288

Oral placebo to TOP1288

Trial Locations (1)

Unknown

PAREXEL Early Phase Clinical Unit, London

All Listed Sponsors
lead

Topivert Pharma Ltd

INDUSTRY

NCT03071081 - Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects | Biotech Hunter | Biotech Hunter